Static Chart Revive Therapeutics Ltd Toronto S.E.

Equities

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+6.67%	-11.11%

23/04	FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	MT
23/04	Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	MT

Duration

Period